adplus-dvertising
Connect with us

Business

COVID-19 vaccine's protection against virus outweighs potential allergy risk, expert says – CBC.ca

Published

 on


Health Canada on Saturday advised people with allergies to any of the ingredients in the Pfizer-BioNTech COVID-19 vaccine not to get it, but one doctor said the news shouldn’t discourage those who are eligible from getting inoculated.

“I don’t think Canadians should be too worried,” Dr. Zain Chagla, an infectious disease physician and associate professor of medicine at McMaster University in Hamilton, told CBC News on Saturday.

The announcement from Health Canada comes after two people in the U.K. had severe allergic reactions to the Pfizer-BioNTech vaccine. The agency said both individuals recovered and had histories of severe allergic reactions.

Health Canada said it is monitoring the situation with British health authorities and the vaccine’s manufacturer, and will take any new action if more issues come up.

Chagla said the likelihood of an allergic reaction is “not common at all,” but commended health authorities on being transparent about the risk and sharing the components of the vaccine that could trigger a reaction.

“You do have to communicate out that there may be risks, and rightfully so, and also communicate about the magnitude of that risk and get people to really understand what that means,” he said. “The risk of an allergy happening is probably beyond winning the lottery — that’s not to say it’s not going to happen, but it’s something we need to watch for, it’s something we’re equipped for.

“At the end of the day, it’s probably not going to happen.”

‘COVID-19 is not a benign diagnosis’

The Pfizer-BioNTech vaccine is the only COVID-19 vaccine approved for use so far by Health Canada, although the federal government has also ordered millions of doses of other manufacturers’ vaccines. Canada’s mass inoculation campaign is expected to begin in a few days.

Chagla also stressed that health officials will be monitoring for other reactions to COVID-19 vaccines that may show up over time. He said communication and transparency are the best ways to assuage vaccine hesitancy — as well as clearly stating to those who are eligible the risks of not getting the vaccine.

“COVID-19 is not a benign diagnosis,” Chagla said. “As much as people fixate on the adverse reactions — which are rare — there is an adverse effect of getting COVID-19.”

Britain began its inoculation program earlier this week. After the reports of the allergic reactions, the country’s medicine regulator advised that anyone with a history of anaphylaxis to a medicine or food should not get the Pfizer-BioNTech vaccine.

WATCH | U.K. warns those with severe allergies should avoid COVID-19 vaccine for now:

The Pfizer-BioNTech COVID-19 vaccine caused an allergic reaction in two health-care workers in the U.K. prompting warnings from health officials there for people with severe allergies to hold off taking the vaccine. 3:23

In the U.S., top Food and Drug Administration (FDA) regulators said on Saturday that only people who have previously had severe allergic reactions to vaccines or ingredients in the Pfizer-BioNTech vaccine should avoid getting the shot. But, they said most Americans with allergies should be safe to receive this particular vaccine. 

“We’re telling people that unless they’ve had a severe allergic reaction to the vaccine, or one of its components, they can receive it,” Dr. Peter Marks, director of the FDA division that authorized the vaccine, said at a press conference.

Pfizer executives said on Friday that there had been no cases of severe allergic reactions to the vaccine during its nearly 44,000 volunteer late-stage clinical trial. That trial excluded people with a history of severe allergic reactions to any vaccine or to the Pfizer-BioNTech vaccine’s ingredients.

They said there were no anaphylactic episodes related to the vaccine in the trial, which did include about 6,000 participants respectively in both the vaccine and placebo groups with a range of allergic conditions such as pollen allergies and food allergies. Those participants had a history of symptoms including anaphylaxis.


The following are the ingredients in the Pfizer-BioNTech vaccine:

Medicinal ingredient:

Non-medicinal ingredients:

  • ALC-0315 = ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate).
  • ALC-0159 = 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide.
  • 1,2-Distearoyl-sn-glycero-3-phosphocholine.
  • Cholesterol.
  • Dibasic sodium phosphate dihydrate.
  • Monobasic potassium phosphate.
  • Potassium chloride.
  • Sodium chloride.
  • Sucrose.
  • Water for injection.

Let’s block ads! (Why?)

728x90x4

Source link

Continue Reading

Business

Japan’s SoftBank returns to profit after gains at Vision Fund and other investments

Published

 on

 

TOKYO (AP) — Japanese technology group SoftBank swung back to profitability in the July-September quarter, boosted by positive results in its Vision Fund investments.

Tokyo-based SoftBank Group Corp. reported Tuesday a fiscal second quarter profit of nearly 1.18 trillion yen ($7.7 billion), compared with a 931 billion yen loss in the year-earlier period.

Quarterly sales edged up about 6% to nearly 1.77 trillion yen ($11.5 billion).

SoftBank credited income from royalties and licensing related to its holdings in Arm, a computer chip-designing company, whose business spans smartphones, data centers, networking equipment, automotive, consumer electronic devices, and AI applications.

The results were also helped by the absence of losses related to SoftBank’s investment in office-space sharing venture WeWork, which hit the previous fiscal year.

WeWork, which filed for Chapter 11 bankruptcy protection in 2023, emerged from Chapter 11 in June.

SoftBank has benefitted in recent months from rising share prices in some investment, such as U.S.-based e-commerce company Coupang, Chinese mobility provider DiDi Global and Bytedance, the Chinese developer of TikTok.

SoftBank’s financial results tend to swing wildly, partly because of its sprawling investment portfolio that includes search engine Yahoo, Chinese retailer Alibaba, and artificial intelligence company Nvidia.

SoftBank makes investments in a variety of companies that it groups together in a series of Vision Funds.

The company’s founder, Masayoshi Son, is a pioneer in technology investment in Japan. SoftBank Group does not give earnings forecasts.

___

Yuri Kageyama is on X:

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Trump campaign promises unlikely to harm entrepreneurship: Shopify CFO

Published

 on

 

Shopify Inc. executives brushed off concerns that incoming U.S. President Donald Trump will be a major detriment to many of the company’s merchants.

“There’s nothing in what we’ve heard from Trump, nor would there have been anything from (Democratic candidate) Kamala (Harris), which we think impacts the overall state of new business formation and entrepreneurship,” Shopify’s chief financial officer Jeff Hoffmeister told analysts on a call Tuesday.

“We still feel really good about all the merchants out there, all the entrepreneurs that want to start new businesses and that’s obviously not going to change with the administration.”

Hoffmeister’s comments come a week after Trump, a Republican businessman, trounced Harris in an election that will soon return him to the Oval Office.

On the campaign trail, he threatened to impose tariffs of 60 per cent on imports from China and roughly 10 per cent to 20 per cent on goods from all other countries.

If the president-elect makes good on the promise, many worry the cost of operating will soar for companies, including customers of Shopify, which sells e-commerce software to small businesses but also brands as big as Kylie Cosmetics and Victoria’s Secret.

These merchants may feel they have no choice but to pass on the increases to customers, perhaps sparking more inflation.

If Trump’s tariffs do come to fruition, Shopify’s president Harley Finkelstein pointed out China is “not a huge area” for Shopify.

However, “we can’t anticipate what every presidential administration is going to do,” he cautioned.

He likened the uncertainty facing the business community to the COVID-19 pandemic where Shopify had to help companies migrate online.

“Our job is no matter what comes the way of our merchants, we provide them with tools and service and support for them to navigate it really well,” he said.

Finkelstein was questioned about the forthcoming U.S. leadership change on a call meant to delve into Shopify’s latest earnings, which sent shares soaring 27 per cent to $158.63 shortly after Tuesday’s market open.

The Ottawa-based company, which keeps its books in U.S. dollars, reported US$828 million in net income for its third quarter, up from US$718 million in the same quarter last year, as its revenue rose 26 per cent.

Revenue for the period ended Sept. 30 totalled US$2.16 billion, up from US$1.71 billion a year earlier.

Subscription solutions revenue reached US$610 million, up from US$486 million in the same quarter last year.

Merchant solutions revenue amounted to US$1.55 billion, up from US$1.23 billion.

Shopify’s net income excluding the impact of equity investments totalled US$344 million for the quarter, up from US$173 million in the same quarter last year.

Daniel Chan, a TD Cowen analyst, said the results show Shopify has a leadership position in the e-commerce world and “a continued ability to gain market share.”

In its outlook for its fourth quarter of 2024, the company said it expects revenue to grow at a mid-to-high-twenties percentage rate on a year-over-year basis.

“Q4 guidance suggests Shopify will finish the year strong, with better-than-expected revenue growth and operating margin,” Chan pointed out in a note to investors.

This report by The Canadian Press was first published Nov. 12, 2024.

Companies in this story: (TSX:SHOP)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

RioCan cuts nearly 10 per cent staff in efficiency push as condo market slows

Published

 on

 

TORONTO – RioCan Real Estate Investment Trust says it has cut almost 10 per cent of its staff as it deals with a slowdown in the condo market and overall pushes for greater efficiency.

The company says the cuts, which amount to around 60 employees based on its last annual filing, will mean about $9 million in restructuring charges and should translate to about $8 million in annualized cash savings.

The job cuts come as RioCan and others scale back condo development plans as the market softens, but chief executive Jonathan Gitlin says the reductions were from a companywide efficiency effort.

RioCan says it doesn’t plan to start any new construction of mixed-use properties this year and well into 2025 as it adjusts to the shifting market demand.

The company reported a net income of $96.9 million in the third quarter, up from a loss of $73.5 million last year, as it saw a $159 million boost from a favourable change in the fair value of investment properties.

RioCan reported what it says is a record-breaking 97.8 per cent occupancy rate in the quarter including retail committed occupancy of 98.6 per cent.

This report by The Canadian Press was first published Nov. 12, 2024.

Companies in this story: (TSX:REI.UN)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending